Skip to content

Clinical Application of a Dermal Substitute based on glycerol preserved Allograft: GLYADERM® A multicentre, prospective, controlled, randomized, comparative trial of Glyaderm® and split thickness skin graft versus split thickness skin graft alone in full thickness skin defects

Clinical Application of a Dermal Substitute based on glycerol preserved Allograft: GLYADERM® A multicentre, prospective, controlled, randomized, comparative trial of Glyaderm® and split thickness skin graft versus split thickness skin graft alone in full thickness skin defects - Multicentre evaluation Glyaderm®

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON36554
Enrollment
36
Registered
2011-03-02
Start date
2011-10-25
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

burn wounds full thickness skin defects

Interventions

All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allogr

Sponsors

Euro Tissue Bank
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • All clearly full thickness burns or skin defects (TBSA Full Thickness Burn

Exclusion criteria

Exclusion criteria: •All partial thickness burns that can heal by conservative treatment •Patients younger than 18 years of age •TBSA > 30 % •Study wound smaller than 100 cm² or greater than 800cm2. •No follow-up till wound closure or withdrawal before start of follow-up •Patient has any condition(s) that seriously compromises the patient*s ability to complete this study •Patient has participated in another study utilizing an investigational drug within the previous 30 days •Patient has one or more medical condition(s), diabetes, including renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the investigator would make the patient an inappropriate candidate for this study

Design outcomes

Primary

MeasureTime frame
Scar elasticity 12 months post wound healing

Secondary

MeasureTime frame
1. percentage of Glyaderm® take before application of autografts, 2. healing time and percentage of autograft survival 3. bacterial load 4. scar quality, objective and subjective assessments 4. cost*effectiveness and health related quality of life study (i.e. cost utility analysis).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)